Administration ’s Special 301 Report highlights deteriorating global environment for biopharmaceutical innovation

In the latest publication of its annualSpecial 301 Report, the Office of the U.S. Trade Representative (USTR) brings renewed attention to intellectual property (IP) and market access challenges in overseas markets that are harming American innovators, patients, and workers.PhRMA is encouraged by the Administration ’s emphasis on the importance of enforcing obligations in existing trade agreements and bilateral discussions. We view the report as a potential basis for engaging trading partners to more effectively address negative practices and regain a level-playing field for American companies – particular ly those that rely heavily on IP protections like companies in the innovative biopharmaceutical industry. 
Source: The Catalyst - Category: Pharmaceuticals Authors: Tags: Intellectual Property 301 Report trade Source Type: news